The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:
* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.
* To identify the optimal length of anticoagulation in the treatment of LV Thrombus
After randomisation participants will:
* Continue their prescribed oral anticoagulant for the remainder of the trial
* Discontinue their prescribed oral anticoagulant for the remainder of the trial

Start Date01 Dec 2026

Sponsor / Collaborator

Queen Mary University of London

NCT07468448

/ Not yet recruitingPhase 3IIT

Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)

CATIS-ICAS is a double-blind, randomized, placebo-controlled (RCT), phase III study seeking to demonstrate that oral rivaroxaban 2.5 mg twice daily plus aspirin daily is superior to clopidogrel 75 mg daily plus aspirin daily for 90 days followed by placebo plus aspirin daily for preventing recurrent stroke in those with ischemic stroke secondary to intracranial atherosclerotic disease (ICAD) of 30-99%, when started within 30 days of index stroke.

Start Date30 Sep 2026

Sponsor / Collaborator

Population Health Research Institute

NCT05900388

/ Not yet recruitingNot Applicable

Xarelto Paediatric VTE PASS Drug Utilization Study: An Observational, Longitudinal, Multi-source Drug Utilization Safety Study to Evaluate the Drug Use Patterns and Safety of Rivaroxaban Oral Suspension in Children Under Two Years With Venous Thromboembolism

This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
VTE is a condition in which blood clots form in the veins, usually in the leg. This can cause pain and swelling. The clot can also break apart and travel in the blood to the lungs where it can block the blood flow. This can be life threatening.
Rivaroxaban is approved for doctors to prescribe to children with VTE, but there is limited information about how it is used, how well it works, and how safe it is in children under 2 years old. Children in this study are already receiving or will receive rivaroxaban or other currently used medicines for VTE from their doctor according to the approved product information.
The purpose of this study is to collect information on the pattern of use and safety of rivaroxaban and other standard medicines for VTE in children under 2 years old.
The main information that researchers will collect in this study:
* Age, gender, and other information about the child and their illness
* Type of VTE treatment given to the child
* Occurrence of medically important bleeding and its severity
Further information that researchers will collect:
* Changes in the characteristics of the children given VTE treatment (e.g., changes in the age range of children given VTE treatment) and changes in the treatment pattern for VTE
* Return of VTE symptoms
* Types of doctors who prescribe VTE treatment and their set-up (e.g., special clinics versus hospitals) Besides this data collection, no further tests or examinations are needed in this study.
The data for this study will be collected from electronic health records and health insurance claims data until 2026.
Researchers will observe each child during treatment until:
* end of the anticoagulation treatment period e.g. discontinuation of all study drugs,
* their information is no longer available, or
* the study ends.

Start Date01 Sep 2026

Sponsor / Collaborator

Bayer AG

[+1]

100 Clinical Results associated with Rivaroxaban

100 Translational Medicine associated with Rivaroxaban

100 Patents (Medical) associated with Rivaroxaban

8,105

Literatures (Medical) associated with Rivaroxaban

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Plain language summary examining clinical event related costs associated with changing medication from apixaban to rivaroxaban in people with non-valvular atrial fibrillation in the USA and Germany

Article

Author: Dworatzek, Elke ; Duan, Cecilia ; Kongnakorn, Thitima ; Zhang, Michelle ; Hines, Dionne M. ; Subash, Rupesh ; Kisser, Agnes

31 Dec 2026·RENAL FAILURE

Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis

Review

Author: Liu, Xin ; Meng, Jie ; Zhou, Yilun ; Wu, Xiaoyuan ; Yang, Yu ; Sheng, Dacheng

This study aimed to evaluate the comparative efficacy and safety of apixaban and rivaroxaban versus vitamin K antagonists (VKAs) in anticoagulation management in a dialysis population. PubMed, Embase, and the Cochrane Library were searched for studies comparing apixaban or rivaroxaban with VKAs in patients with atrial fibrillation (AF) undergoing dialysis. The primary efficacy endpoints included stroke/systemic embolism (SSE) and all-cause mortality. Safety outcomes encompassed major bleeding, intracranial hemorrhage, and gastrointestinal bleeding. Risk ratios (RR) with 95% confidence intervals (CI) were synthesized using random-effects models. The meta-analysis included three randomized controlled trials (RCTs) and eight observational studies. Pooled analyses showed that apixaban and rivaroxaban were associated with lower risks of major bleeding (RR 0.57, 95% CI: 0.51-0.63), gastrointestinal bleeding (RR 0.66, 95% CI: 0.57-0.76), and intracranial hemorrhage (RR 0.54, 95% CI: 0.36-0.83) compared with VKAs. Additionally, apixaban and rivaroxaban were associated with reduced risk of SSE (RR 0.57, 95% CI: 0.46-0.72) and all-cause mortality (RR 0.73, 95% CI:0.63-0.83), although substantial heterogeneity was present. Exploratory dose-stratified analyses suggested both standard- and low-dose apixaban regimens were associated with favorable efficacy and hemostatic safety relative to warfarin. Consistent numerical trends were observed in the RCT-only analysis, though none reached statistical significance owing to limited sample size. In conclusion, apixaban and rivaroxaban are associated with lower risks of bleeding compared with VKAs in patients with AF and ESRD. However, evidence regarding their efficacy in preventing SSE, all-cause mortality and the optimal apixaban dosing regimen remains inconclusive and requires validation in large, dedicated RCTs.

31 Dec 2026·NMC case report journal

Gradual Occlusion of an Anterior Choroidal Artery Aneurysm Using Overlapping Flow Diversion and Short-term Anticoagulation: A Case Report

Article

Author: KUROSAKI, Masamichi ; SAKAMOTO, Makoto ; KAMBE, Atsushi ; YOSHIOKA, Hiroki ; KESUMAYADI, Irfan ; UNO, Tetsuji

Anterior choroidal artery aneurysms, in which the anterior choroidal artery arises from the aneurysmal sac, pose significant therapeutic challenges, as treatment risks include branch occlusion and devastating ischemic complications, including hemiplegia and hemianopia. We report a patient in their 70s with an incidentally diagnosed 12.2 mm unruptured right anterior choroidal artery aneurysm, in which three-dimensional angiography demonstrated that the anterior choroidal artery originated from the center of the aneurysm dome. During conservative observation, the aneurysm enlarged to 14.1 mm, necessitating intervention. We employed overlapping flow diverters (2 Pipeline Shield devices) with minimal loose coiling to facilitate controlled thrombosis. To prevent rapid aneurysm thrombosis and subsequent anterior choroidal artery occlusion, we administered modified triple antithrombotic therapy comprising dual antiplatelet agents (prasugrel 3.75 mg and aspirin 100 mg) and reduced-dose rivaroxaban (10 mg daily) for 30 days postoperatively. At 12-month follow-up, angiography demonstrated near-complete aneurysm occlusion (O'Kelly-Marotta grade C3) and a significant reduction in aneurysm size. Critically, during gradual aneurysmal shrinkage, the orifice of the anterior choroidal artery progressively migrated toward the aneurysm neck, allowing branch preservation while the sac underwent organized thrombosis. No perioperative or delayed ischemic complications occurred, and magnetic resonance imaging confirmed the absence of new infarction. This controlled thrombosis strategy combining mechanical flow diversion with time-limited pharmacological modulation successfully achieved aneurysm occlusion while preserving the sac-originating branch through gradual vascular remodeling. This approach addresses the fundamental therapeutic dilemma posed by anterior choroidal artery aneurysms with incorporated branches. It may represent a paradigm shift from acute treatment to controlled, gradual occlusion strategies for similarly challenging lesions.

369

News (Medical) associated with Rivaroxaban

17 Sep 2026

·www.fiercepharma.com

Bayer’s Kerendia secures FDA nod as first drug in 30 years for Type 1 diabetes-associated kidney disease

Bayer just scored another label expansion for its blockbuster-in-waiting, Kerendia. The heart and kidney med earned the first FDA nod in three decades for adults with chronic kidney disease associated with type 1 diabetes. Kerendia, also known as finerenone, was approved to reduce urinary albumin-to-creatine ratio (UACR), a key risk factor of worsening CKD, in patients with type 1 diabetes associated CKD. According to Bayer, the drug stands to benefit 30% of the estimated 2 million U.S. type 1 diabetes patients who will develop CKD within their lifetime. UACR reduction with Kerendia is expected to reduce the risk of kidney disease progression in type 1 diabetes-associated CKD, including declining kidney filtration rates and end-stage kidney disease. The FDA decision was based on findings from Kerendia’s phase 3 Fine-one clinical trial in adult patients with CKD associated with type 1 diabetes. The 242-subject trial showed that Kerendia reduced UACR by more than 25% after 6 months, with benefits observed as early as 3 months. The data builds on Bayer’s clinical trial work in CKD associated with type 2 diabetes, which demonstrated that UACR is an important marker of CKD progression. In Bayer’s Fidelio-DKD and Figaro-DKD trials, UACR reduction with Kerendia was associated with improved kidney outcomes, including lower rates of kidney failure, sustained decrease in estimated glomerular filtration, and renal death. The approval “provides an important new treatment option for a population that has continued to face substantial unmet need,” said Janet McGill, M.D., from Washington University School of Medicine in St. Louis and co-chair of the Fine-one study’s executive committee. Kerendia is now the only non-steroidal mineralocorticoid receptor antagonist (MRA) indicated for adults with type 1 or type 2 diabetes-associated CKD. The label expansion marks the drug’s third indication since 2021, when it was first approved for type 2 diabetes-associated CKD. Then, last year, it picked up an approval for two types of heart failure: with preserved ejection fraction and mildly reduced ejection fraction. Bayer has more extensions up its sleeve after a phase 3 win in two of the most common forms of non-diabetic CKD earlier this spring. Continued regulatory and commercial momentum for Kerendia is critical to Bayer’s overall growth strategy. The drug is key to offsetting losses as older medications like Xarelto and Eylea face increasing generic and biosimilar competition. In the second quarter of 2026, the two older products saw sales decline 42.4% and 32.8%, respectively, for Bayer. While Bayer’s overall pharmaceutical sales were flat for Q2 , Kerendia’s sales proved to be a bright spot, demonstrating a better-than-expected 83% increase year-over-year. The company is now predicting peak annual sales for the drug will climb to $3 billion.

Drug ApprovalPhase 3Clinical Result

09 Sep 2026

·www.biospace.com

BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION

GIRK4 (BAY 3670549) is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor being evaluated as a potential new approach to control the electrical activity of cardiomyocytes in patients with atrial fibrillation (AFib) AFib is the most common type of sustained cardiac arrhythmia (irregular heart rhythm), affecting more than 60 million people worldwide, and a significant risk factor for stroke and heart failure 1,2,3 Positive data from the Phase I first-in-human, dose-escalation study supports advancing GIRK4 inhibitor to the next phase of development Derived from the strategic research alliance with the Broad Institute of MIT and Harvard, BAY 3670549 further strengthens Bayer’s cardiovascular development portfolio Not intended for UK Media WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the initiation of a global Phase II clinical trial ( NCT07625215 ) evaluating BAY 3670549, an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor, which has the potential as a new approach to control the electrical activity of heart cells in patients with atrial fibrillation (AFib). The Phase II single-treatment study in a randomized, double-blind, placebo-controlled, parallel-group, multi-cohort design, will investigate the efficacy, safety and tolerability, as well as pharmacodynamics and pharmacokinetics of BAY 3670549 in adult patients with AFib. BAY 3670549 showed a generally favorable safety and tolerability pro healthy participants in the completed first-in-human single-ascending-dose Phase I study, supporting its continued clinical advancement and strengthening Bayer’s cardiovascular development portfolio. BAY 3670549, which emerged from Bayer’s strategic research alliance with the Broad Institute, is being investigated as a novel approach for rapid cardioversion to normal sinus rhythm. If successful, it could provide a potential alternative to electrical cardioversion, the current gold standard for AFib. AFib is the most common type of sustained cardiac arrhythmia (irregular heart rhythm), affecting more than 60 million people worldwide, and a significant risk factor for stroke and heart failure. 4,5,6 About GIRK4 inhibitor (BAY 3670549) BAY 3670549 is an investigational highly selective G-protein-coupled inwardly rectifying potassium channel 4 (GIRK4) inhibitor being evaluated as a potential new approach to help control the electrical activity of heart cells in patients with atrial fibrillation (AFib). GIRK4 channels are specialized proteins that regulate the electrical activity of heart cells by facilitating the flow of potassium ions (K+) in response to the neurotransmitter acetylcholine (ACh). This mechanism is particularly crucial during the later phases of the heart’s electrical signaling, specifically during the atrial effective refractory period (AERP). Increased activity of these channels shortens the AERP in the atria (the upper chambers of the heart), thereby reducing the recovery time after each heartbeat. This alteration in recovery time can contribute to the onset and persistence of AFib. About the study ( NCT07625215 ) A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase II study will investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with AFib. The study will compare BAY 3670549 to a placebo in patients with AFib who need a treatment called electrical cardioversion. Electrical cardioversion is a procedure that helps the heart return to a normal rhythm. In the Phase I study, BAY 3670549 was generally well-tolerated in healthy male and female participants. About Atrial fibrillation AFib is one of the most common sustained cardiac rhythm disorders (arrhythmias). It results from rapid, disorganized electrical signals in the upper chambers (atria) of the heart, causing them to quiver and contract quickly and irregularly. As a result, the atria do not empty efficiently, leading to impaired blood flow and an increased risk of blood clot formation. These clots can break loose, travel to the brain, and cause a stroke. In addition, AFib disrupts the coordinated function of the upper and lower chambers of the heart, impairing overall cardiac performance and leading to symptoms such as palpitations, shortness of breath, fatigue, and a reduced quality of life in many patients. The prevalence of AFib continues to increase globally. Projection studies show that the number of people with AFib will rise to 15.9 million in 2050 in America and 17.9 million in 2060 in Europe. 7 People with AFib are 5 times more likely to suffer a stroke than people without AFib. 8 AFib-related strokes are also associated with a 50% likelihood of death within one year. 9 About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to . Find more information at Follow us on Facebook: aka (2026-0153e) Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ____________________________ 1 Atrial fibrillation: epidemiology, screening and digital health , Linz, Dominik et al., The Lancet Regional Health – Europe, Volume 37, 100786 2 American Heart Association, Why Atrial Fibrillation Matters | American Heart Association 3 Kornej J, Benjamin EJ, Magnani JW, Atrial fibrillation: global burdens and global opportunities, Heart 2021;107:516-518. 4 Atrial fibrillation: epidemiology, screening and digital health , Linz, Dominik et al., The Lancet Regional Health – Europe, Volume 37, 100786 5 American Heart Association, Why Atrial Fibrillation Matters | American Heart Association 6 Kornej J, Benjamin EJ, Magnani JW, Atrial fibrillation: global burdens and global opportunities, Heart 2021;107:516-518. 7 Atrial fibrillation: epidemiology, screening and digital health, Linz, Dominik et al., The Lancet Regional Health – Europe, Volume 37, 100786 8 Singleton MJ, Imtiaz‐Ahmad M, Kamel H, O'Neal WT, Judd SE, Howard VJ, Howard G, Soliman EZ, Bhave PD. Association of atrial fibrillation without cardiovascular comorbidities and stroke risk: from the REGARDS study. Journal of the American Heart Association. 2020 Jun 16;9(12):e016380. 9 Alberts M, Chen YW, Lin JH, Kogan E, Twyman K, Milentijevic D. Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin. Stroke. 2020 Feb;51(2):549-555. doi: 10.1161/STROKEAHA.119.025554. Epub 2019 Dec 31. PMID: 31888412; PMCID: PMC7004448. Contacts Bayer U.S. Media Contact: Elaine Colon, phone +1 732 236 1587 Email: elaine.colon@bayer.com Bayer Media Contact: Anna Kanmaz, phone +49 174 146 3541 Email: anna.kanmaz@bayer.com

Phase 1Phase 2Clinical ResultAHA

08 Sep 2026

·www.prnewswire.com

Clinical Science Update | New Clinical Evidence for ClotChek™

The information contained herein represents a summary of the peer-reviewed journal article published in Thrombosis and Haemostasis entitled " Clinical Validation of a Point-of-Care Whole Blood Coagulometer in Patients on Factor Xa Inhibitors" DANBURY, Conn., Sept. 8, 2026 /PRNewswire/ -- Perosphere Technologies Inc. (Perosphere), a medical technology company developing next-generation coagulation diagnostics, today announced that a new clinical study evaluating the Perosphere ClotChek™ rapid, point-of-care coagulometer has been published in the international journal Thrombosis and Haemostasis. Continue Reading Perosphere ClotChek™ The study evaluated ClotChek Clotting Time (CKCT) in patients receiving Factor Xa (FXa) inhibitors apixaban and rivaroxaban, demonstrating DOAC-sensitivity and strong correlations between the CKCT and the DOAC related anti-FXa drug levels when patients were categorized based on meaningful Medical Decision Limits (MDL), as well as the ability to detect clinically meaningful anticoagulation at both >75 ng/mL and >30 ng/mL MDL thresholds. "These findings support the potential for ClotChek to address a longstanding unmet clinical need for rapid, bedside assessment of DOAC anticoagulant effect. Results can help inform decision making in time-sensitive patient scenarios such as major bleeding, acute ischemic stroke, trauma, and emergent surgery," said Sasha Bakhru, PhD, co-author and CEO of Perosphere. Importantly, ClotChek provides a pharmacodynamic measurement of a patient's coagulation status in whole blood, without reagents, and demonstrated sensitivity at lower drug concentrations, where knowing how anticoagulated a patient is can be particularly important when making critical decisions. "Without rapid, objective assessment of anticoagulation status for DOAC patients, clinicians may be forced to make empiric treatment decisions - or even delay or defer potentially time-sensitive interventions," said Dr. Jack Ansell, MD, co-author and former Chairman, Department of Medicine at Lenox Hill Hospital. Congratulations to Drs. Bakhru, Connors, Ansell, Giugliano (of the TIMI Study Group) and all the investigators, on this important work, which continues to advance the field of point-of-care coagulation testing. Learn more about Perosphere Technologies and ClotChek™ at perospheretech.com. About Perosphere Perosphere develops point-of-care diagnostics to support informed clinical decision-making for patients receiving anticoagulant therapy or at risk of bleeding. The Perosphere ClotChek™ is a DOAC-sensitive coagulometer designed to rapidly measure whole blood clotting time in 3–8 minutes. Perosphere ClotChek is CE marked in the European Union and is not cleared for use by the FDA in the United States. Media Contact: John Friedl | Perosphere, Director of Marketing [email protected] +1 (949) 485-0465 Company Contact: Perosphere [email protected] +1 (475) 218-4600 SOURCE Perosphere Technologies Inc. 21% more press release views with Request a Demo

Clinical Result

100 Deals associated with Rivaroxaban

External Link

KEGG	Wiki	ATC	Drug Bank
D07086	Rivaroxaban	B01AF01	DB06228

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Coronary Disease	United States	Janssen Pharmaceuticals, Inc.	24 Mar 2026
Thromboembolism	Japan	Bayer Yakuhin Ltd.	24 Nov 2023
Thrombosis	United States	Janssen Pharmaceuticals, Inc.	20 Dec 2021
Atherosclerosis	European Union	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Iceland	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Liechtenstein	Viatris Ltd. (New Zealand)	12 Nov 2021
Atherosclerosis	Norway	Viatris Ltd. (New Zealand)	12 Nov 2021
Atrial Fibrillation	China	Bayer AG	31 Mar 2009
Myocardial Infarction	Australia	Bayer Australia Ltd.	24 Nov 2008
Recurrent deep vein thrombosis	Australia	Bayer Australia Ltd.	24 Nov 2008
Stroke	Australia	Bayer Australia Ltd.	24 Nov 2008
Systemic embolism	Australia	Bayer Australia Ltd.	24 Nov 2008
Acute Coronary Syndrome	European Union	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Iceland	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Liechtenstein	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	Norway	Bayer AG	30 Sep 2008
Acute Coronary Syndrome	United Kingdom	Bayer Plc	30 Sep 2008
Embolism	European Union	Bayer AG	30 Sep 2008
Embolism	Iceland	Bayer AG	30 Sep 2008
Embolism	Liechtenstein	Bayer AG	30 Sep 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cardiovascular Diseases	Phase 3	Australia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Belgium	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Canada	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	France	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Germany	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	India	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Malaysia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Nepal	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Saudi Arabia	Bayer AG	18 Jan 2021
Cardiovascular Diseases	Phase 3	Singapore	Bayer AG	18 Jan 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESC2026	Not Applicable	Atrial Fibrillation	115,040	On-label DOAC dosing	esljvazdvg(fcytxqpoct) = zhcdpeeskw iqgomawuts (ejnqqvlhlc ) View more	Positive	28 Aug 2026
ESC2026	Not Applicable	Atrial Fibrillation	115,040	Off-label DOAC dosing	esljvazdvg(fcytxqpoct) = lrrqihfdvf iqgomawuts (ejnqqvlhlc ) View more	Positive	28 Aug 2026
NCT05546320 (Pubmed \| BMJ)	Phase 2	Migraine Disorders	984	Aspirin 300 mg once daily	qomuvmodft(pawiqjwkno) = dlgdiuifzw ddkptreivn (vnsjdlqkdn )	Positive	29 Jul 2026
NCT05546320 (Pubmed \| BMJ)	Phase 2	Migraine Disorders	984	Clopidogrel 75 mg once daily	qomuvmodft(pawiqjwkno) = sjvnzwhnxg ddkptreivn (vnsjdlqkdn )	Positive	29 Jul 2026
NCT03969953 (Pubmed \| JAMA)	Phase 3	Kidney Diseases	1,458	Rivaroxaban 2.5 mg	smbmzuqeiz(rdpckekhjb) = xhwmvkizbs dhakrzavwf (qpznqechjy ) View more	Negative	28 Jul 2026
NCT03969953 (Pubmed \| JAMA)	Phase 3	Kidney Diseases	1,458	Placebo	smbmzuqeiz(rdpckekhjb) = mpbcchzqox dhakrzavwf (qpznqechjy ) View more	Negative	28 Jul 2026
ISTH2026	Not Applicable	Thrombosis	34	Direct oral anticoagulants (DOACs)	tdvahyxcfm(aqpbewebjn) = tmskjubhjb wsuioikjbn (wdmlevhain ) View more	Positive	13 Jul 2026
ISTH2026	Not Applicable	Venous Thromboembolism	57	Rivaroxaban (VTE treatment)	wxkweqmmgz(wcyhxuxfva) = jwtqultpkz vxznzyjcrd (vxctaqqoic )	Positive	13 Jul 2026
ISTH2026	Not Applicable	Short Bowel Syndrome	20	Rivaroxaban	fgljqsjgss(alflmhkqnb) = qjqoxzwjwt xevvpgszix (jwdbolfsgn, 41 - 206) View more	Positive	13 Jul 2026
ISTH2026	Not Applicable	-	205	Rivaroxaban 10mg daily	fgkbtwzpkk(hwzatnrkgo) = yotgoxtghl prtgpchdmz (aenifdxghg ) View more	Positive	13 Jul 2026
ISTH2026	Not Applicable	Multiple Myeloma	20	Low-dose aspirin	losxmdhuhu(kgbcdlyzku) = nqrwiqxweh lruqmgslni (upyylssspt )	Positive	13 Jul 2026
ISTH2026	Not Applicable	Multiple Myeloma	20	DOACs (rivaroxaban 15-20 mg OD)	dytmtolyka(lgqevystze) = vsfpqhozmj hzvvvddygb (dhxakdoytb )	Positive	13 Jul 2026
ISTH2026	Not Applicable	Thrombosis	60	Apixaban	wosavsiazp(uyeyuuaxlw) = pmwhowypxo fjughqsxta (zyjqlsbdnl ) View more	Positive	13 Jul 2026
ISTH2026	Not Applicable	Venous Thromboembolism	330	Low doses of DOACs (rivaroxaban 10 mg once daily, apixaban 2.5 mg twice daily, or edoxaban 30 mg once daily)	spyibrhcej(gufgyoogfv) = qejbgrgxxy ckdviqctuo (vrmnfbauim ) View more	Positive	12 Jul 2026

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis